Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first FDA, European Union ("EU") Regulation No. 2017/745 ("MDR" or "EU Medical Devices Regulation"), and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA.
In the company’s own words · 10-K filed Feb 13, 2026 · SEC EDGAR
Business segments
Jun 2026 · $200.6MThe company’s own SEC segment disclosure.
- United States$187.3M93%
- Non Us$13.3M7%
Inspire Medical Systems, Inc. (INSP) reported revenue of $205M in Q1 2026 (quarter ended Mar 31, 2026), up 1.6% from the same quarter a year earlier. That came with a gross margin of 86% and net loss of $11M. For the full year FY2025, revenue was $912M (+14% year on year) and net income $145M. Its largest region in Jun 2026 was United States at $187M, 93% of the disclosed total, well ahead of Non Us at 6.6%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.